Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
- PMID: 32231328
- PMCID: PMC7104419
- DOI: 10.1038/s41569-020-0368-x
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
Conflict of interest statement
J.-J.M. has received fees for consultancy from Mylan, Pfizer and Servier. B.I.L. has received grants and personal fees from Bayer, Roche and Servier.
Comment in
-
Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.Nat Rev Cardiol. 2020 May;17(5):313-314. doi: 10.1038/s41569-020-0369-9. Nat Rev Cardiol. 2020. PMID: 32231330 Free PMC article. No abstract available.
-
Mechanisms by which angiotensin-receptor blockers increase ACE2 levels.Nat Rev Cardiol. 2020 Jun;17(6):378. doi: 10.1038/s41569-020-0387-7. Nat Rev Cardiol. 2020. PMID: 32332868 Free PMC article. No abstract available.
Comment on
-
COVID-19 and the cardiovascular system.Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. Nat Rev Cardiol. 2020. PMID: 32139904 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources